Pharmaceutical opioid marketing and physician prescribing behavior

Svetlana Beilfuss and Sebastian Linde

Health Economics, 2021, vol. 30, issue 12, 3159-3185

Abstract: Physicians' relationships with the pharmaceutical industry have recently come under public scrutiny, particularly in the context of opioid drug prescribing. This study examines the effect of doctor‐industry marketing interactions on subsequent prescribing patterns of opioids using linked Medicare Part D and Open Payments data for the years 2014–2017. Results indicate that both the number and the dollar‐value of marketing visits increase physicians' patented opioid claims. Furthermore, direct‐to‐physician marketing of safer abuse‐deterrent formulations of opioids is the primary driver of positive and persistent spillovers on the prescribing of less safe generic opioids ‐ a result that we show appears to be driven by insurance coverage policies. These findings suggest that pharmaceutical marketing efforts may have unintended public health implications.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1002/hec.4424

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:30:y:2021:i:12:p:3159-3185

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().